Noveris Health Sciences Inc., formerly Mydecine Innovations Group Inc., is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with scientific and regulatory expertise.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	87.82M 62.49M 54.66M 50.57M 46.42M 6.02B 89.41M 603M 236M 2.95B 235M 230M 10.15B	P/E 2024	-0.19x	P/E 2025	0.13x
Enterprise Value	97.4M 69.31M 60.62M 56.09M 51.48M 6.68B 99.15M 669M 262M 3.27B 260M 255M 11.26B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.95%	Yield 2024 *	-	Yield 2025	-

06-12	Noveris Health Sciences Appoints Nathan Mison as Chair of Advisory Board	CI
05-29	Noveris Health Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Noveris Health Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-30	Noveris Health Sciences Inc. Auditor Raises 'Going Concern' Doubt	CI
04-28	Noveris Health Sciences Inc. signed a term sheet to acquire 49% stake in ELL Stem Cells for $1 million.	CI
03-17	Noveris Health Sciences Inc. announced that it has received CAD 2.310012 million in funding	CI
03-12	Noveris Health Sciences Inc. announced that it expects to receive CAD 2.5 million in funding	CI
03-10	Noveris Health Sciences Inc. Announces Board Changes	CI
03-10	Noveris Health Sciences Inc. Announces CEO Changes	CI
02-02	Noveris Health Sciences Inc. will Change its Ticker to NVRS from MYCO	CI
02-02	Mydecine Innovations Group Inc. will Change its Name to Noveris Health Sciences Inc	CI
11-18	Noveris Health Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-13	Noveris Health Sciences Inc. announced that it has received CAD 7.878792 million in funding from Pioneer Garage Limited	CI

07-14	Noveris Health Sciences Joins Life Sciences BC	AQ
06-29	Noveris Health Sciences Announces Upcoming AGM and Record Date, and receipt of CSE Notice	AQ
06-12	Noveris Health Sciences Announces Appointment Of Nathan Mison As Chair Of Advisory Board	AQ
06-08	Noveris Health Sciences Appoints Geoff Griffiths As Strategic Advisor To Support Commercialization And Growth Initiatives	AQ
06-05	Noveris Health Sciences Provides Corporate Update	AQ

Manager	Title	Age	Since
Jason Birmingham CEO	Chief Executive Officer	53	2026-03-09
John Ross DFI	Director of Finance/CFO	67	2022-09-15

Director	Title	Age	Since
Michael Callas BRD	Director/Board Member	-	2025-03-20
Peter Field BRD	Director/Board Member	-	2025-03-17
Jason Birmingham BRD	Director/Board Member	53	2026-03-09

New Age Farm Inc Stock Canadian Securities Exchange

Stocks

CA64157D1087

Biotechnology & Medical Research

Valuation: New Age Farm Inc

Latest news : New Age Farm Inc

Press Releases: New Age Farm Inc

Quotes and Performance

Managers and Directors: New Age Farm Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEW AGE FARM INC	-8.33%	+33.33%	-	-	62.52M
LONZA GROUP AG	-1.07%	+0.38%	+2.06%	+5.66%	50.35B
REVOLUTION MEDICINES, INC.	-2.85%	-5.58%	+373.90%	+572.09%	39.21B
IQVIA HOLDINGS INC.	+1.78%	+3.29%	+33.49%	-4.80%	34.52B
BEONE MEDICINES AG	+1.98%	+5.15%	+17.69%	+61.68%	34.6B
CELLTRION, INC.	+0.06%	-0.57%	+3.35%	+27.42%	27.05B
ASCENDIS PHARMA A/S	-3.27%	-6.27%	-	-	16.68B
MEDPACE HOLDINGS, INC.	+1.64%	+1.11%	+72.02%	+121.18%	15.11B
EUROFINS SCIENTIFIC SE	+0.29%	+3.64%	+15.30%	+17.80%	13.85B
ICON PUBLIC LIMITED COMPANY	-1.21%	+2.74%	+16.77%	-30.96%	13.18B
Average	-0.85%	+0.81%	+66.82%	+96.26%	27.17B
Weighted average by Cap.	+0.08%	+0.70%	+79.63%	+118.91%

	2024	2025
Net sales	-	-
Net income	-3.15M -2.24M -1.96M -1.82M -1.67M -216M -3.21M -21.64M -8.47M -106M -8.43M -8.25M -364M	2.92M 2.08M 1.82M 1.68M 1.54M 200M 2.97M 20.05M 7.85M 98.09M 7.81M 7.64M 338M
Net Debt	6.87M 4.89M 4.28M 3.96M 3.63M 471M 7M 47.19M 18.48M 231M 18.39M 17.98M 795M	9.57M 6.81M 5.96M 5.51M 5.06M 656M 9.75M 65.72M 25.73M 321M 25.6M 25.05M 1.11B